As we near the five-year anniversary of the COVID-19 pandemic, it's a good time to revisit the drugmaker stock that was top ...

Shares of vaccine-maker Moderna MRNA closed at $34.71 on Monday, close to their 52-week low of $29.25. Moderna is facing several headwinds, including the declining COVID-19 vaccine and the soft sales ...

Ward said it would be good to see data from studies of other variant vaccine boosters to compare to the Moderna combination. Expert advisors "must already be thinking about the population at risk ...

Moderna recently experienced a notable 10% price increase over the last week amidst significant legal and financial developments. Genevant Sciences and Arbutus Biopharma have expanded their patent ...

U.S. health officials are reevaluating a $590 million contract that was awarded to Moderna for the development of its bird flu vaccine, Bloomberg News reported on Wednesday, citing sources.

based Moderna by the Biomedical Advanced Research ... triggered an adequate immune response and to generate the safety data the FDA would want to see would be done in advance.

One of the most underappreciated applications of artificial intelligence in the corporate world involves its role in writing ...

Moderna Inc.’s stock erased early losses to gain more than 3% on Friday, after the biotech company posted a wider-than-expected fourth-quarter loss and offered soft guidance for 2025, offsetting ...

German court rules Pfizer, BioNTech violated Moderna's COVID-19 vaccine patent ... while investors focused on data pointing to a cooling U.S. economy. Novavax sees royalties, reduced expenses ...

UBS believes Moderna’s oncology franchise is underappreciated onto melanoma Phase 3 data despite unknowns around the Covid/respiratory franchise, the analyst tells investors in a research note.

Barclays 27th Annual Global Healthcare Conference March 11, 2025 1:30 PM ETCompany ParticipantsRose Loughlin - EVP of ...

Madison Mills examines the trending headlines Wall Street investors need to know on today's Market Minute. BlackRock (BLK) stock is in focus as the company takes the lead on the $22.8 billion deal ...